Dimerix Ltd (ASX:DXB) Share Price

Company Profile

Business description
Dimerix Ltd is a biopharmaceutical company developing new therapies in areas with unmet medical needs. The company is developing four product candidates: DMX-200 for FSGS; DMX-200 for diabetic kidney disease; DMX-200 for ARDS associated with COVID-19; and DMX-700 for COPD, as well as the proprietary ReceptorHIT assay technology. It pursues new product concepts and applies deep scientific knowledge to the discovery of products from early-stage development through to commercialisation. Dimerix products will target multiple territories. The Group has only operated in one Segment, being investment in research and development of biopharmaceutical drugs.
Contact
425 Smith Street
FitzroyVIC3065
AUS
T: +61 1300813321
https://www.dimerix.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
9

Recommended

Here’s a wide-moat company with strong secular tailwinds in a promising industry—and an attractive stock price, too.

Malik Ahmed Khan, CFA | 08 January 2026

Wagering continues to be challenged in Australia.

Angus Hewitt, CFA | 08 January 2026

Rising inflation is the fly in the ointment.

Simonelle Mody | 08 January 2026

Index	Last price	Change	% Change
All Ordinaries	9,045.90	27.80	-0.31%
CAC 40	8,284.76	50.84	0.62%
DAX 40	25,140.08	12.62	0.05%
Dow JONES (US)	49,266.11	270.03	0.55%
FTSE 100	10,078.61	33.92	0.34%
HKSE	26,231.79	82.48	0.32%
NASDAQ	23,480.02	104.26	-0.44%
Nikkei 225	51,939.89	822.63	1.61%
NZX 50 Index	13,696.25	20.61	-0.15%
S&P 500	6,921.46	0.53	0.01%
S&P/ASX 200	8,717.80	29.10	-0.33%
SSE Composite Index	4,120.43	37.45	0.92%